[ad_1]
Benchmark increased their price objective on Ligand Pharmaceuticals from $160.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday.
[ad_2]
Source link
Related Posts
AerSale Corporation (NASDAQ:ASLE) Director Judith Ann Fedder Buys 2,100 Shares
[ad_1] AerSale Corporation (NASDAQ:ASLE – Get Free Report) Director Judith Ann Fedder purchased 2,100 shares of the stock in a…
IQ EQ FUND MANAGEMENT IRELAND Ltd Takes $359,000 Position in Schrodinger, Inc. (NASDAQ:SDGR)
[ad_1] IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in Schrodinger, Inc. (NASDAQ:SDGR – Free Report) during the…
One of the world’s most polluted cities has banned single-use plastics. It’s not so easy
[ad_1] LAGOS, Nigeria (AP) — Nigerian shop manager Olarewanju Ogunbona says he uses Styrofoam and plastic packs at least five…